Skip to content

Study · Measured the body's own peptide · 1985

4 results

Ontogeny of vasoactive intestinal peptide and somatostatin in different structures of the rat brain: effects of hypo- and hypercorticism.

Nobou F, Besson J, Rostene W, Rosselin G

Brain research1 Jun 1985Cited by 14 (Europe PMC)

PMID2862962 (opens in a new tab)DOI10.1016/0165-3806(85)90118-x (opens in a new tab)PepBankPUB-02862962
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In the developing rat CNS, natural VIP appeared only after birth, whereas somatostatin was present before birth in every structure tested.

    In plain wordsIn rats, the body's own VIP appeared in brain structures only after birth, while somatostatin was already present before birth.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableOnset of VIP in rat CNS structures versus somatostatin
    Study

    ratn: not reported in source

    Outcome group
    Aging markers · Nervous system and cognition

    Source sentences

    Summary
    The evolution of both peptides was different since SRIF was found before birth in each structure tested while VIP appeared only after birth in the same structures.
    1 context sentence
    Summary · context
    The ontogeny of the vasoactive intestinal peptide (VIP) and somatostatin (SRIF) was studied in various structures of the rat central nervous system (CNS), using specific radioimmunoassays. The effect of adrenal corticoids on the concentration of both peptides was investigated during the development…

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Other

    After birth, natural VIP in rat CNS structures followed a pattern similar to somatostatin, with the maximum concentration between day 14 and day 21.

    In plain wordsIn rats, the body's own VIP in brain structures reached its highest level between day 14 and day 21 after birth.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicablePostnatal peak of VIP in rat CNS
    Study

    ratn: not reported in source

    Outcome group
    Aging markers · Nervous system and cognition

    Source sentences

    Summary
    However, after birth the ontogeny of VIP and SRIF was quite similar and the maximum concentration of both peptides occurred between day 14 and day 21.
    1 context sentence
    Summary · context
    The ontogeny of the vasoactive intestinal peptide (VIP) and somatostatin (SRIF) was studied in various structures of the rat central nervous system (CNS), using specific radioimmunoassays. The effect of adrenal corticoids on the concentration of both peptides was investigated during the development…

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Other

    In developing rats, corticosterone implants (hypercorticism) changed the postnatal pattern of natural VIP in the CNS; the direction is not stated.

    In plain wordsIn rats, high corticosteroid levels changed how the body's own VIP in the brain developed after birth.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Direction not reportedVIP after hypercorticism (corticosterone implant)
    Study

    ratn: not reported in source

    Outcome group
    Aging markers · Nervous system and cognition

    Source sentences

    Summary
    Hypercorticism (implant of corticosterone) and hypocorticism (Metyrapone injections) modified the postnatal evolution of both peptides, suggesting that corticoids play an important role in the brain developmental patterns of VIP and SRIF.
    1 context sentence
    Summary · context
    The ontogeny of the vasoactive intestinal peptide (VIP) and somatostatin (SRIF) was studied in various structures of the rat central nervous system (CNS), using specific radioimmunoassays. The effect of adrenal corticoids on the concentration of both peptides was investigated during the development…

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  4. 04AnimalEndogenous levelAnimal study (in vivo)Other

    In developing rats, metyrapone injections (hypocorticism) changed the postnatal pattern of natural VIP in the CNS; the direction is not stated.

    In plain wordsIn rats, low corticosteroid levels changed how the body's own VIP in the brain developed after birth.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Direction not reportedVIP after hypocorticism (metyrapone injections)
    Study

    ratn: not reported in source

    Outcome group
    Aging markers · Nervous system and cognition

    Source sentences

    Summary
    Hypercorticism (implant of corticosterone) and hypocorticism (Metyrapone injections) modified the postnatal evolution of both peptides, suggesting that corticoids play an important role in the brain developmental patterns of VIP and SRIF.
    1 context sentence
    Summary · context
    The ontogeny of the vasoactive intestinal peptide (VIP) and somatostatin (SRIF) was studied in various structures of the rat central nervous system (CNS), using specific radioimmunoassays. The effect of adrenal corticoids on the concentration of both peptides was investigated during the development…

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.